Sangamo Therapeutics Announces Chief Financial Officer Succession
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Piper Jaffray Remains Sidelined on Sangamo Biosciences (SGMO) Following 4Q Report
February 28, 2017 12:01 PM ESTPiper Jaffray reiterated a Neutral rating and $5.00 price target on Sangamo BioSciences (NASDAQ: SGMO) following the company's 4Q earnings report. Sangamo reported 4Q16 revenues of $8.9M, slightly above projections, and opex of $18.8M, slightly below projections.
Analyst Charles Duncan commented, "Today Sangamo reported 4Q16 financial... More
